CN113559062A - 一种含有静电纺丝纤维的抗菌喷剂的制备方法 - Google Patents
一种含有静电纺丝纤维的抗菌喷剂的制备方法 Download PDFInfo
- Publication number
- CN113559062A CN113559062A CN202110823343.8A CN202110823343A CN113559062A CN 113559062 A CN113559062 A CN 113559062A CN 202110823343 A CN202110823343 A CN 202110823343A CN 113559062 A CN113559062 A CN 113559062A
- Authority
- CN
- China
- Prior art keywords
- electrostatic spinning
- antibacterial
- spinning
- fibers
- organic solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000010041 electrostatic spinning Methods 0.000 title claims abstract description 62
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 35
- 239000007921 spray Substances 0.000 title claims abstract description 27
- 239000000835 fiber Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- NRBJWZSFNGZBFQ-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 NRBJWZSFNGZBFQ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960004055 ciprofloxacin lactate Drugs 0.000 claims abstract description 14
- 229960001180 norfloxacin Drugs 0.000 claims abstract description 14
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 claims abstract description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 33
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 22
- 239000012528 membrane Substances 0.000 claims description 22
- 238000009987 spinning Methods 0.000 claims description 22
- 239000003960 organic solvent Substances 0.000 claims description 15
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 14
- 229940124350 antibacterial drug Drugs 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 8
- 238000005507 spraying Methods 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 239000011888 foil Substances 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract description 6
- 239000002105 nanoparticle Substances 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 3
- 230000007547 defect Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 12
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002121 nanofiber Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F1/00—General methods for the manufacture of artificial filaments or the like
- D01F1/02—Addition of substances to the spinning solution or to the melt
- D01F1/10—Other agents for modifying properties
- D01F1/103—Agents inhibiting growth of microorganisms
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/88—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds
- D01F6/92—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds of polyesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Dispersion Chemistry (AREA)
- Textile Engineering (AREA)
- Hematology (AREA)
- Manufacturing & Machinery (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种含有静电纺丝纤维的抗菌喷剂的制备方法，包括：含有乳酸环丙沙星或诺氟沙星的静电纺丝液的配制；含有乳酸环丙沙星或诺氟沙星的静电纺丝纤维的制作；含有乳酸环丙沙星或诺氟沙星的静电纺丝短纤维的制备；将含有乳酸环丙沙星或诺氟沙星的静电纺丝短纤维和75％酒精进行混合，获得具有长效抗菌效果的喷剂。本发明技术方案提升抗菌喷剂的持久性，避免对人体造成伤害，解决市场上成分单一的喷剂或抗菌纳米颗粒的缺陷。
Description
技术领域
本发明涉及抗菌喷剂技术领域，特别涉及一种含有静电纺丝纤维的抗菌喷剂的制备方法。
背景技术
静电纺丝纳米纤维由于其较大的孔隙结构以及优异的载药性，在组织再生以及医药领域具有良好的应用价值。目前市场上使用的抗菌喷剂，由于组成成分比较明确，往往由特定具有抗菌作用的药物按照一定比例溶解到特定的溶剂混合而成，抗菌效果不持久，具有一定的局限性；经过修饰的纳米颗粒虽然同样具有优秀的抗菌效果，但是纳米颗粒往往容易进入人体皮肤细胞造成细胞毒性。
因此，现有技术存在缺陷，需要改进。
发明内容
本发明的主要目的是提出一种含有静电纺丝纤维的抗菌喷剂的制备方法，旨在提升抗菌喷剂的持久性，避免对人体造成伤害，解决市场上成分单一的喷剂或抗菌纳米颗粒的缺陷。
为实现上述目的，本发明提出的一种含有静电纺丝纤维的抗菌喷剂的制备方法，包括如下步骤：
S1：配置纺丝液
将纺丝溶质溶解于有机溶剂中，并加入抗菌药物，其中，所述纺丝溶质与有机溶剂的质量与体积比为10～12％，所述抗菌药物与有机溶剂的质量与体积比为0.3～0.7％，所述纺丝溶质包括PLGA或PLA中的一种或两种的组合，所述抗菌药物包括诺氟沙星或乳酸环丙沙星中的一种或两种的组合，所述有机溶剂包括氯仿、丙酮、N,N二甲基甲酰胺中的一种或至少两种的组合；
S2：对纺丝液进行静电纺丝
将步骤S1中配置的纺丝液放入静电纺丝机中进行静电纺丝，其中，静电纺丝机电喷条件为：电压20-30kV，接收距离7～14cm，注射器的推进速率为0.5mL/h，环境温度为20-30℃，湿度为60-70％，还包括用于接收静电纺丝膜的接收装置；
S3：静电纺丝短纤维的制备
当接收装置上的静电纺丝膜达到一定厚度后，将静电纺丝膜取出并将纤维打碎，收集备用；
S4：抗菌喷剂的制备
将收集的打碎后的静电纺丝膜添加至75％酒精中，或得抗菌喷剂，其中，添加的静电纺丝膜与75％酒精之间的质量与体积比为1％或2％或5％或7％或9％或10％或12％或15％。
优选地，所述纺丝溶质设置为PLA或PLGA中的一种。
优选地，所述抗菌药物设置为诺氟沙星或乳酸环丙沙星中的一种。
优选地，所述有机溶剂包括氯仿、丙酮及N,N二甲基甲酰胺，且所述氯仿、丙酮及N,N二甲基甲酰胺之间的体积比为2：1：3。
优选地，所述接收装置设置为装锡箔纸。
优选地，步骤S3具体包括：当接收装置上的静电纺丝膜达到一定厚度后，将静电纺丝膜取下，用剪刀剪成1cm3大小的小块，随后将小块置于10000rpm/min的高速搅拌器中，搅拌1-2h，待静电纺丝膜纤维全部打碎，收集备用。
与现有技术相比，本发明的有益效果是：
1、方法流程简单，操作实施方便；
2、采用绿色环保无公害的PLA或PLGA材料制作微球界面或纳米纤维膜，具有很好的生物相容性。
3、本发明制作的PLGA或PLA静电纺丝膜，具有优良的载药效果，在体外具有长效的药物释放效果，可以达到14天以上；
4、本发明获得的含有PLGA或PLA静电纺丝纤维的抗菌喷剂，可以按照不同比例和75％酒精进行混合，分布均匀，并且使用方便。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案，下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍，显而易见地，下面描述中的附图仅仅是本发明的一些实施例，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图示出的结构获得其他的附图。
图1为本发明包裹有乳酸环丙沙星的静电纺丝膜示意图；
图2为本发明包裹有诺氟沙星的静电纺丝膜示意图；
图3为本发明抗菌喷剂制备流程示意图；
本发明目的的实现、功能特点及优点将结合实施例，参照附图做进一步说明。
具体实施方式
本实施例提出的一种含有静电纺丝纤维的抗菌喷剂的制备方法，包括如下步骤：
S1：配置纺丝液
将纺丝溶质溶解于有机溶剂中，并加入抗菌药物，其中，所述纺丝溶质与有机溶剂的质量与体积比为10～12％，所述抗菌药物与有机溶剂的质量与体积比为0.3～0.7％，所述纺丝溶质包括PLGA或PLA中的一种或两种的组合，所述抗菌药物包括诺氟沙星或乳酸环丙沙星中的一种或两种的组合，所述有机溶剂包括氯仿、丙酮、N,N二甲基甲酰胺中的一种或至少两种的组合；
S2：对纺丝液进行静电纺丝
将步骤S1中配置的纺丝液放入静电纺丝机中进行静电纺丝，其中，静电纺丝机电喷条件为：电压20-30kV，接收距离7～14cm，注射器的推进速率为0.5mL/h，环境温度为20-30℃，湿度为60-70％，还包括用于接收静电纺丝膜的接收装置；
S3：静电纺丝短纤维的制备
当接收装置上的静电纺丝膜达到一定厚度后，将静电纺丝膜取出并将纤维打碎，收集备用；
S4：抗菌喷剂的制备
将收集的打碎后的静电纺丝膜添加至75％酒精中，或得抗菌喷剂，其中，添加的静电纺丝膜与75％酒精之间的质量与体积比为1％或2％或5％或7％或9％或10％或12％或15％。
进一步地，所述纺丝溶质设置为PLA或PLGA中的一种。
进一步地，所述抗菌药物设置为诺氟沙星或乳酸环丙沙星中的一种。
进一步地，所述有机溶剂包括氯仿、丙酮及N,N二甲基甲酰胺，且所述氯仿、丙酮及N,N二甲基甲酰胺之间的体积比为2：1：3。
进一步地，所述接收装置设置为装锡箔纸。
进一步地，步骤S3具体包括：当接收装置上的静电纺丝膜达到一定厚度后，将静电纺丝膜取下，用剪刀剪成1cm3大小的小块，随后将小块置于10000rpm/min的高速搅拌器中，搅拌1-2h，待静电纺丝膜纤维全部打碎，收集备用。
应当说明的是本发明通过静电纺丝技术获得的PLGA或PLA静电纺丝纤维包裹了一定比例的乳酸环丙沙星或诺氟沙星，具有很好的抗菌作用，并且能够持续抗菌达14天以上；同时PLGA或PLA属于纯天然绿色无公害材料，具有优秀的降解性能，不会对人体造成伤害，很好的解决了市场上成分单一的喷剂或抗菌纳米颗粒的缺陷。
以下，通过具体实施例对本申请进行说明：
以10mL静电纺丝液体系为例，量筒准确量取N,N二甲基甲酰胺5mL，氯仿3.4mL，丙酮1.7mL；电子天平称取PLGA或PLA材料1.2g，乳酸环丙沙星或诺氟沙星0.04g，随后将称量好的PLGA或PLA以及乳酸环丙沙星或诺氟沙星倒入混合好的氯仿、丙酮、N,N二甲基甲酰胺溶液中，震荡搅拌1.5h，直至PLGA或PLA完全溶解；
将配置好的纺丝液放入静电纺丝机中进行静电纺丝，其中，静电纺丝机电喷条件为：电压20-30kV，接收距离7～14cm，注射器的推进速率为0.5mL/h，环境温度为25℃，湿度为65％，接收装置设置为装锡箔纸；
静电纺丝膜到一定厚度后，将静电纺丝膜取下，用剪刀剪成1cm3大小的小块，随后将小块置于10000rpm/min的高速搅拌器中，搅拌1-2h，待静电纺丝膜限位全部打碎，收集备用；
将收集的打碎后的静电纺丝膜添加至75％酒精中，分别按照1％，2％，5％，7％，9％，10％，12％，15％的比例混合静电纺丝短纤维，获得具有不同抗菌性能的喷剂。
进一步地，将上述实施例制得的纳米纤维进行抗菌实验，过程如下：
1、琼脂培养基的配制与灭菌；
2、菌悬液的制备：在洁净工作台中，用无菌棉签刮取金黄色葡萄球菌和大肠杆菌菌落至无菌pH值为7.0的氯化钠-蛋白胨溶液中，用6*108cfu/mL的比浊管进行对比，达到其浓度后进行梯度稀释，达到最终菌液浓度为6*105cfu/mL，随后采用无菌棉签蘸取6*105cfu/mL溶液，在胰酪大豆胨琼脂培养基培养皿上均匀涂抹；
3、抑菌样品的贴放：将制作好的静电纺丝膜剪取直径面积为5mm大小的样片，轻轻按压于涂抹有菌的培养皿中，盖好平皿，置于培养箱中培养16-18h。
4、抑菌作用判断：抑菌环大于7mm者，具有抗菌作用。
具体地，本实施例制备的纳米纱的抑菌效果如下表所示：
| 大肠杆菌 | 金黄色葡萄球菌 | |
| 样品1 | 21.03mm | 17.33mm |
| 样品2 | 22.14mm | 19.31mm |
| 样品3 | 19.42mm | 19.24mm |
以上仅为本发明的优选实施例，并非因此限制本发明的专利范围，凡是利用本发明说明书及附图内容所作的等效结构或等效流程变换，或直接或间接运用在其他相关的技术领域，均同理包括在本发明的专利保护范围内。
Claims (6)
1.一种含有静电纺丝纤维的抗菌喷剂的制备方法，其特征在于，包括如下步骤：
S1：配置纺丝液
将纺丝溶质溶解于有机溶剂中，并加入抗菌药物，其中，所述纺丝溶质与有机溶剂的质量与体积比为10～12％，所述抗菌药物与有机溶剂的质量与体积比为0.3～0.7％，所述纺丝溶质包括PLGA或PLA中的一种或两种的组合，所述抗菌药物包括诺氟沙星或乳酸环丙沙星中的一种或两种的组合，所述有机溶剂包括氯仿、丙酮、N,N二甲基甲酰胺中的一种或至少两种的组合；
S2：对纺丝液进行静电纺丝
将步骤S1中配置的纺丝液放入静电纺丝机中进行静电纺丝，其中，静电纺丝机电喷条件为：电压20-30kV，接收距离7～14cm，注射器的推进速率为0.5mL/h，环境温度为20-30℃，湿度为60-70％，还包括用于接收静电纺丝膜的接收装置；
S3：静电纺丝短纤维的制备
当接收装置上的静电纺丝膜达到一定厚度后，将静电纺丝膜取出并将纤维打碎，收集备用；
S4：抗菌喷剂的制备
将收集的打碎后的静电纺丝膜添加至75％酒精中，或得抗菌喷剂，其中，添加的静电纺丝膜与75％酒精之间的质量与体积比为1％或2％或5％或7％或9％或10％或12％或15％。
2.如权利要求1所述的含有静电纺丝纤维的抗菌喷剂的制备方法，其特征在于，所述纺丝溶质设置为PLA或PLGA中的一种。
3.如权利要求1所述的含有静电纺丝纤维的抗菌喷剂的制备方法，其特征在于，所述抗菌药物设置为诺氟沙星或乳酸环丙沙星中的一种。
4.如权利要求1所述的含有静电纺丝纤维的抗菌喷剂的制备方法，其特征在于，所述有机溶剂包括氯仿、丙酮及N,N二甲基甲酰胺，且所述氯仿、丙酮及N,N二甲基甲酰胺之间的体积比为2：1：3。
5.如权利要求1所述的含有静电纺丝纤维的抗菌喷剂的制备方法，其特征在于，所述接收装置设置为装锡箔纸。
6.如权利要求1所述的含有静电纺丝纤维的抗菌喷剂的制备方法，其特征在于，步骤S3具体包括：当接收装置上的静电纺丝膜达到一定厚度后，将静电纺丝膜取下，用剪刀剪成1cm3大小的小块，随后将小块置于10000rpm/min的高速搅拌器中，搅拌1-2h，待静电纺丝膜纤维全部打碎，收集备用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110823343.8A CN113559062A (zh) | 2021-07-20 | 2021-07-20 | 一种含有静电纺丝纤维的抗菌喷剂的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110823343.8A CN113559062A (zh) | 2021-07-20 | 2021-07-20 | 一种含有静电纺丝纤维的抗菌喷剂的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113559062A true CN113559062A (zh) | 2021-10-29 |
Family
ID=78165991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110823343.8A Pending CN113559062A (zh) | 2021-07-20 | 2021-07-20 | 一种含有静电纺丝纤维的抗菌喷剂的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113559062A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114164505A (zh) * | 2021-11-15 | 2022-03-11 | 新乡市中心医院 | 一种震荡辅助的静电纺丝方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107308137A (zh) * | 2017-07-05 | 2017-11-03 | 西南大学 | 一种载姜黄素抗菌纤维膜及其制备方法 |
| CN112755254A (zh) * | 2021-01-18 | 2021-05-07 | 河南农业大学 | 一种具有抗菌作用的气管插管的制备方法 |
-
2021
- 2021-07-20 CN CN202110823343.8A patent/CN113559062A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107308137A (zh) * | 2017-07-05 | 2017-11-03 | 西南大学 | 一种载姜黄素抗菌纤维膜及其制备方法 |
| CN112755254A (zh) * | 2021-01-18 | 2021-05-07 | 河南农业大学 | 一种具有抗菌作用的气管插管的制备方法 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114164505A (zh) * | 2021-11-15 | 2022-03-11 | 新乡市中心医院 | 一种震荡辅助的静电纺丝方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fahimirad et al. | Naturally-derived electrospun wound dressings for target delivery of bio-active agents | |
| Tang et al. | Honey loaded alginate/PVA nanofibrous membrane as potential bioactive wound dressing | |
| Cremar et al. | Development of antimicrobial chitosan based nanofiber dressings for wound healing applications | |
| Kopp et al. | Effect of process parameters on additive-free electrospinning of regenerated silk fibroin nonwovens | |
| CN103536958B (zh) | 一种基于溶菌酶和丝蛋白的层层自组装改性纤维素纳米纤维膜及其制备与应用 | |
| CN107233611A (zh) | 一种多功能纳米纤维创面修复生物敷料及其制备方法 | |
| CN102493126A (zh) | 一种含纳米银的复合纤维材料及其制备方法 | |
| Zhang et al. | Fabrication of green poly (vinyl alcohol) nanofibers using natural deep eutectic solvent for fast-dissolving drug delivery | |
| CN103194856B (zh) | 抗菌、伤口愈合作用的壳聚糖/丝胶复合纳米纤维的制备方法 | |
| Chandika et al. | Enhanced wound-healing capability with inherent antimicrobial activities of usnic acid incorporated poly (ε-caprolactone)/decellularized extracellular matrix nanofibrous scaffold | |
| CN113559062A (zh) | 一种含有静电纺丝纤维的抗菌喷剂的制备方法 | |
| Idumah et al. | A review on biomolecular immobilization of polymeric textile biocomposites, bionanocomposites, and nano-biocomposites | |
| CN103751848A (zh) | 一种抗菌修复型静电纺丝胶原蛋白-细菌纤维素复合纳米纤维支架的制备方法及其应用 | |
| Bhar et al. | Harnessing multifaceted next-generation technologies for improved skin wound healing | |
| CN110152049B (zh) | 一种医用伤口敷料的壳聚糖基纳米纤维膜的应用 | |
| Alam et al. | Collagen/Nigella sativa/chitosan inscribed electrospun hybrid bio-nanocomposites for skin tissue engineering | |
| Yang et al. | A facile, biosynthetic design strategy for high-performance multifunctional bacterial cellulose-based dressing | |
| CN107349473B (zh) | 一种可降解聚乳酸/丝素/壳聚糖复合神经导管及其制备方法 | |
| CN114225090A (zh) | 一种具有粘附性和抗菌性能的壳聚糖基纳米纤维伤口敷料及其制备方法 | |
| CN105944134A (zh) | 一种静电纺高壳聚糖含量的抗菌伤口敷料的制备方法 | |
| Bardsley et al. | Integration of choline geranate into electrospun protein scaffolds affords antimicrobial activity to biomaterials used for cutaneous wound healing | |
| CN115778827B (zh) | 一种高vc载量芯/壳型纳米纤维面膜及其制备方法和应用 | |
| CN109943974B (zh) | 基于聚羟基脂肪酸酯/明胶电纺纳米纤维的神经导管材料的制备方法 | |
| CN105727358B (zh) | 载药生物高分子复合纳米纤维膜及其制备方法 | |
| CN113005633A (zh) | 一种抗菌纳米纤维膜及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211029 |
|
| RJ01 | Rejection of invention patent application after publication |